Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gan and Lee Pharmaceuticals's Revenue for the
three
months ended in Jun. 2026 was ¥1,345 Mil. Gan and Lee Pharmaceuticals's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥583 Mil.
Hence, Gan and Lee Pharmaceuticals's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.31.
Gan and Lee Pharmaceuticals (SHSE:603087) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gan and Lee Pharmaceuticals Receivables Turnover Related Terms
Gan and Lee Pharmaceuticals Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals Receivables Turnover Chart
SHSE:603087 vs ISRG, BDX, RMD: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gan and Lee Pharmaceuticals Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gan and Lee Pharmaceuticals (SHSE:603087) has a Receivables Turnover of 2.31 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gan and Lee Pharmaceuticals and its competitors. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #229 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 28.3%.
Is Gan and Lee Pharmaceuticals' Receivables Turnover too high?
Gan and Lee Pharmaceuticals' current Receivables Turnover is 2.31. The Medical Devices & Instruments industry median Receivables Turnover is 5.62. Gan and Lee Pharmaceuticals' value of 2.31 is 58.9% below this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #229 out of 810 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #229 out of 810 companies for Receivables Turnover. This puts Gan and Lee Pharmaceuticals in the upper half of its industry. The industry median Receivables Turnover is 5.62. Gan and Lee Pharmaceuticals' value of 2.31 is 58.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.62, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Receivables Turnover of 2.31 is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Receivables Turnover is 2.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Receivables Turnover is 2.31 and 58.9% below the Medical Devices & Instruments industry median of 5.62. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Receivables Turnover is 2.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued.
The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00.
GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
Receivables Turnover: 2.31
GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
Industry Position: 58.9% below the Medical Devices & Instruments median (#229 of 810)
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603087 has been successfully added to your 
